Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Xiaomi Corporation surged 3.94 percent and WuXi Biologics tumbled 2.67 percent. The lead from Wall Street is upbeat as the major averages opened higher on Tuesday and mostly stayed that way ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Legislation would have cut Chinese businesses off from US WuXi executives say the companies continue to sign new clients WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other ... ET Despite challenges in the CDMO industry, Samsung Biologics is "well positioned to kick-start a new ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with ...

in market cap Samsung Biologics has kicked off the start of 2025 with the largest single contract in the company's history, signing a record-breaking $1.41 billion deal, amounting to some 40 ...

WuXi Biologics, BGI Group, MGI, and Complete Genomics—citing national security risks tied to China’s involvement in the global pharmaceutical supply chain. Legislation like the Biosecure Act ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in Ireland to US drugs giant Merck Sharp & Dohme for around USD500 million. WuXi ...